サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1712540

生体吸収性インプラントの世界市場 (2025-2033年)

Global Bioresorbable Implants Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
生体吸収性インプラントの世界市場 (2025-2033年)
出版日: 2025年04月22日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の生体吸収性インプラントの市場規模は、2024年の70億米ドルから、予測期間中はCAGR 7.4%で推移し、2033年には143億4,000万米ドルに達すると予測されています。

市場力学：

革新的材料を用いた先進インプラントの開発台頭

革新的材料を用いたインプラントの開発が進む中、生体吸収性インプラント市場の成長が大きく促進されています。材料科学の進歩により、機械的強度、生体適合性、分解速度の制御性を向上させた生体吸収性ポリマーや複合材料が開発されてきました。たとえば、生体活性ガラスやマグネシウムベースの合金をインプラントの設計に組み込むことで、機能性と治癒能力が強化されています。

これらの技術革新により、単に治癒を支えるだけでなく、組織再生を促進するインプラントの開発が可能となり、その応用範囲はさまざまな医療分野へと広がっています。2025年1月には、生体吸収性整形外科用インプラントの先駆者であるBioretecがCEマーク認証プロセスを完了し、同社のRemeOs外傷用スクリューポートフォリオをEU内およびCEマーク認証を認める非欧州諸国において商業展開することが可能となりました。この認証は、中空タイプおよび非中空タイプの全製品設計をカバーしており、直径2.0mm～4.0mm、長さ8mm～50mmのサイズが対象です。承認された適応症には、成人および小児の上肢および下肢（手および前足部を除く）における骨折および骨のアライメント異常の固定が含まれます。

さらに、センサーや薬剤送達システムといったスマート技術を生体吸収性インプラントに組み込むことで、リアルタイムでのモニタリングや標的治療が可能となり、患者の治療効果が一層高まっています。これらの技術的進歩により、生体吸収性インプラントはより効果的かつ多用途になり、臨床現場での採用が加速しています。

当レポートでは、世界の生体吸収性インプラントの市場を調査し、市場概要、市場成長への各種影響因子の分析、各種区分・地域/主要国別の詳細分析、主要企業のプロファイルなどをまとめています。

目次

第1章 市場概要・調査範囲

第2章 エグゼクティブインサイト・重要ポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • 抜粋：材料タイプ別
  • 抜粋：用途別
  • 抜粋：エンドユーザー別
  • 抜粋：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーとパイオニア
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の研究
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析：ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 生体吸収性インプラント市場：材料別

  • メタリック
  • ポリマー
  • PLGA-ポリ乳酸グリコール酸
  • PLLA-ポリL-乳酸
  • PGA-ポリグリコール酸
  • PLA-ポリ乳酸
  • その他

第6章 生体吸収性インプラント市場：用途別

  • 心血管系
  • 整形外科
  • その他

第7章 生体吸収性インプラント市場：エンドユーザー別

  • 病院
  • 外来手術センター
  • その他

第8章 生体吸収性インプラント市場：地域別の分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合情勢の概要・主要企業
  • 市場シェア分析・ポジショニングマトリックス
  • 戦略的パートナーシップ、M&A
  • 製品ポートフォリオとイノベーションにおける主な展開
  • 企業ベンチマーク

第10章 企業プロファイル

  • Bioretec Ltd
  • Stryker Corporation
  • CONMED Corporation
  • Syntellix AG
  • Johnson &Johnson Medical Devices（DePuy Synthes）
  • Zimmer Biomet
  • NuVasive Inc.
  • KLS Martin Group
  • Smith+Nephew
  • Evonik Industries AG

第11章 仮定・調査手法

第12章 付録

目次
Product Code: MD887

The global bioresorbable implants market reached US$ 7.00 billion in 2024 and is expected to reach US$ 14.34 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.

Bioresorbable implants are medical devices made from specially engineered polymers that naturally dissolve or degrade within the body over time, eliminating the need for surgical removal once their function is complete. These implants are composed of either hydrophobic or hydrophilic polymers and are designed to support healing processes in various medical applications, particularly after surgery.

They are available in a wide range of forms and are commonly used in orthopedic procedures, tissue repair, and drug delivery systems. As they gradually break down into non-toxic byproducts that are safely absorbed or excreted by the body, bioresorbable implants offer a less invasive, patient-friendly alternative to permanent implants, reducing the risk of long-term complications and the need for additional surgeries.

Market Dynamics: Drivers & Restraints

Rising Development of Advanced Implants with Innovative Materials

The rising development of implants utilizing innovative materials is significantly driving the growth of the bioresorbable implants market. Advancements in material science have led to the creation of bioresorbable polymers and composites that offer improved mechanical strength, biocompatibility, and controlled degradation rates. For instance, the integration of bioactive glass and magnesium-based alloys into implant designs has enhanced their functionality and healing capabilities.

These innovations enable the development of implants that not only support healing but also promote tissue regeneration, thereby expanding their applications across various medical specialties. In January 2025, Bioretec, a pioneer in absorbable orthopedic implants, has completed its CE mark approval process and can start commercialization of its RemeOs Trauma Screw product portfolio within the European Union and non-European countries that recognize the CE mark market authorization. This comprehensive approval covers all cannulated and non-cannulated product designs, with sizes ranging from diameters of 2.0mm to 4.0mm and lengths from 8mm to 50mm. Indications approved include the use of these screws for fracture and malalignment fixations in both upper and lower extremities of adult and pediatric patients, excluding the hand and forefoot.

Additionally, the incorporation of smart technologies, such as sensors and drug delivery systems, into bioresorbable implants allows for real-time monitoring and targeted treatment, further enhancing patient outcomes. These technological advancements are making bioresorbable implants more effective and versatile, thereby accelerating their adoption in clinical settings.

High Cost of Designing and Manufacturing

The high cost of designing and manufacturing bioresorbable implants remains a major barrier to the market's broader adoption. These implants require advanced materials, specialized production techniques, and extensive research and testing to ensure biocompatibility and precise degradation rates. Processes like 3D printing, polymer blending, and surface modification demand sophisticated equipment and skilled labor, all of which significantly drive up production costs.

Segment Analysis

The global bioresorbable implants market is segmented based on material type, application, and end-user region.

Material Type:

PLGA (Poly lactic-co-glycolic acid) in the material type segment is expected to dominate the bioresorbable implants market.

PLGA (Poly lactic-co-glycolic acid) is expected to dominate the bioresorbable implants market due to its exceptional versatility, safety profile, and broad range of clinical applications. As a copolymer of lactic acid and glycolic acid, PLGA offers customizable degradation rates by simply altering the ratio of its two components, allowing it to be tailored for everything from short-term tissue scaffolds to longer-term orthopedic or cardiovascular support. Its biocompatibility and non-toxic degradation byproducts (carbon dioxide and water) make it ideal for implantation, with minimal risk of inflammation or rejection.

PLGA is already widely used in FDA-approved medical devices, including sutures, screws, pins, and drug-delivery systems, which has established a strong regulatory precedent for new product approvals. Moreover, PLGA's role in controlled drug release has expanded its utility beyond just structural support. Given its proven track record, ease of processing, and adaptability across various specialties like orthopedics, cardiology, and regenerative medicine, the PLGA segment is well-positioned to remain a leading force in the global bioresorbable implants market.

Geographical Analysis

North America is expected to dominate the global bioresorbable implants market.

North America is expected to dominate the bioresorbable implants market due to rising surgical volumes, growing adoption of advanced medical technologies, and increasing demand for patient-friendly treatment options. The region, particularly the United States, has seen a steady rise in procedures such as orthopedic repairs, soft tissue reconstruction, and cardiovascular interventions.

For instance, according to the American College of Rheumatology, in 2024, about 790,000 total knee replacements and 544,000 hip replacements were done every year in the U.S. This number continues to grow as our population ages. This increase in the number of procedures is expected to increase the demand for bioresorbable implants, as a large number of individuals in the region are hesitating about the removal surgery of implants.

Additionally, a strong focus on reducing long-term complications and avoiding secondary surgeries has led to higher acceptance of bioresorbable devices like screws, pins, and plates. Recent product approvals, such as magnesium-based bioresorbable implants, and growing use of materials like PLGA and PLLA further support this trend.

With a well-established regulatory pathway and a high level of awareness among healthcare providers, North America is expected to maintain its leading position in the global bioresorbable implants market. For instance, In March 2023, Bioretec Ltd received the market authorization of the U.S. Food and Drug Administration (FDA) for its pioneering RemeOs trauma screw to be used for healing of bone fractures aligned with the clinical trial.

Competitive Landscape

The global market players in the bioresorbable implants market include Bioretec Ltd, Stryker Corporation, CONMED Corporation, Syntellix AG, Johnson & Johnson Medical Devices (DePuy Synthes), Zimmer Biomet, NuVasive Inc., KLS Martin Group, Smith+Nephew, Evonik Industries AG, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global bioresorbable implants market report will provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Material Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Number of Approvals
      • 3.1.1.2. Rising Development of Implants with Innovative Materials
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Designing and Manufacturing
      • 3.1.2.2. Limited Awareness Among Healthcare Professionals
    • 3.1.3. Opportunity
      • 3.1.3.1. Shift Toward Minimally Invasive and Patient-centric Healthcare Solutions
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Bioresorbable Implants Market, By Material Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 5.1.2. Market Attractiveness Index, By Material Type
  • 5.2. Metallic*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Polymers
  • 5.4. PLGA- Poly lactic-co-glycolic acid
  • 5.5. PLLA- Poly L-lactide
  • 5.6. PGA- Polyglycolic Acid
  • 5.7. PLA- Polylactic Acid
  • 5.8. Others

6. Bioresorbable Implants Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Cardiovascular*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Orthopedics
  • 6.4. Others

7. Bioresorbable Implants Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Others

8. Bioresorbable Implants Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Bioretec Ltd*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Stryker Corporation
  • 10.3. CONMED Corporation
  • 10.4. Syntellix AG
  • 10.5. Johnson & Johnson Medical Devices (DePuy Synthes)
  • 10.6. Zimmer Biomet
  • 10.7. NuVasive Inc.
  • 10.8. KLS Martin Group
  • 10.9. Smith+Nephew
  • 10.10. Evonik Industries AG
  • indicates "similar data will be provided for each market player."

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us